Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL

Key Points

• Survival outcomes appear better with CAR-T and bispecific T-cell engagers in relapsed/refractory DLBCL patients, indicating promise for treatment options.
• Key evidence shows a significant improvement in survival rates compared to historical controls, particularly in patients who have exhausted traditional therapies.
• This analysis involved a retrospective cohort study of DLBCL patients treated with CAR-T and bispecific T-cell engagers across multiple centers.
• The findings support the potential benefits of these novel therapies for enhancing patient survival in relapsed/refractory situations.